Vida Ventures

Activity in this selectionjefferson-life-sciences-dd9e1469

By stage

Series A2

Series B2

Series C+1

Biotech4

Healthtech1

United States4

Denmark1

5 in this selection

Aug 12

Develops proximity-guided antibody-drug conjugate therapeutics for cancer and autoimmune disease

$77MSeries B

Role not disclosed

Jun 10

Develops ultrasound-mediated nonviral genetic medicines

$125MSeries B

Role not disclosed

Apr 14

Develops first- and best-in-class antibody-drug conjugates (ADCs) for cancer treatment

$75MSeries C

Role not disclosed

Mar 3

Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions

$45MSeries A+

Role not disclosed

Jan 7

Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions

$50MSeries A

Role not disclosed